Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
06.05.2024 - Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced ...
United States South San Francisco Fred Hutch American Association For Cancer Research Development Expenses Lyell Immunopharma Inc
Source: wallstreet-online.de